ALLOGENE THERAPEUTICS INC (ALLO)
Health Care · biotechnology / immunotherapy · NASDAQ
Allogene Therapeutics is pioneering off-the-shelf, allogeneic CAR T cell therapies to provide faster, more scalable treatment options for cancer and autoimmune patients compared to traditional autologous approaches.
What ALLOGENE THERAPEUTICS INC does
Allogene Therapeutics is a clinical-stage immuno-oncology company developing off-the-shelf, allogeneic T-cell therapies derived from healthy donors. Its pipeline focuses on treating cancer and autoimmune diseases, including large B-cell lymphoma (LBCL), renal cell carcinoma (RCC), and various autoimmune conditions like systemic lupus erythematosus. The company utilizes proprietary gene-editing technologies and its Dagger® platform to create standardized, readily available therapies designed to overcome the limitations of traditional, patient-specific autologous CAR T cell treatments.
Recent developments
The FDA granted RMAT and Fast Track designations to cema-cel following positive interim results from the ALPHA3 pivotal trial, which showed 58.3% MRD negativity compared to 16.7% in the control arm. The company accelerated its site activation schedule, now targeting approximately 100 active sites by the end of 2026. Clinical updates for the ALLO-329 autoimmune program are expected in Q4 2026.
From ALLOGENE THERAPEUTICS INC's filing of 2026-08-12.
Themes: allogeneic CAR T, off-the-shelf cell therapy, immuno-oncology, autoimmune disease therapy, minimal residual disease (MRD) testing
Fundamentals
- Price$1.40 as of 2026-10-08 close
- Market cap$484M as of 2026-08-10 (share count; price 2026-10-08)
- 1-year return-4.8% 2025-10-08 close $1.47 → 2026-10-08 close $1.40
- P/En/a negative earnings
- ROE-65.3% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Beta1.46 as of 2026-09-03
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How ALLO compares in its sector
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ALLOGENE THERAPEUTICS INC looks technically
ALLOGENE THERAPEUTICS INC (ALLO) is trading 29.5% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 21 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 41, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 20, in oversold territory (below 30). It just made a new 20-day low, its first since 2026-01-05, breaking below its recent trading range. It is 68.6% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 29.5% below its 200-day average, the long-term trend line — a long-term downtrend | -29.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.85 | $1.85 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.99 | $1.99 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 50 calendar days ago — the swings before that are what the structure reading is measured on | 50 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 2.23. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 21 trading days ago — a "death cross", a bearish long-term signal | 21 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 41, with sellers in control | 41.2 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 20, in oversold territory (below 30) | 20.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($1.34 to $1.74) — its "stochastic" reading is 14 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 13.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 29 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $4.46 | $4.46 |
|---|---|---|
| From the 52-week high | it is 68.6% below its 52-week high (its highest price of the past year) | -68.6% |
| Above the 52-week low | it is 34.6% above its 52-week low (its lowest price of the past year) | +34.6% |
| Below the 52-week high | it is 68.6% below its highest point of the past year | 68.6% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-01-05, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, its first since 2026-01-05, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $55.00 (set on 2020-05-26) | $55.00 |
| Given back of the 52-week move | over the past year its closes ranged ($1.05 to $3.06), and it has given back almost all of its rise from last year’s low — 83% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.75 to $1.82. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 82.6% |
| From the all-time high | it is 97.5% below its all-time high | -97.5% |
| Nearest price level | it is trading 8.6% below a resistance level at $1.52 — a price it turned at twice since 2025-06-10, most recently on 2025-10-09. Since 2024-10-08 it has 0 such levels below the current price and 12 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +8.6% |
| All-time low | its lowest closing price on record is $0.8621 (set on 2025-05-14) | $0.8621 |
| Above the all-time low | it is 62.4% above its all-time low | +62.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 60th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0846 between its high and its low — about 6.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0846 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.40 and $1.85 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.40 – $1.62 – $1.85 |
| Typical daily range (% of price) | its price moves about 6.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.0% |
| Stretch from the 200-day average | it is trading 6.9 daily ranges below its 200-day average price (29.5% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.9 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.48× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.7% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.7% |
|---|---|---|
| Open gap | it gapped 2.0% below the previous close 22 sessions ago and has not traded back through the level it left behind at 1.97 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.0% |
| Gap filled | a 3.0% gap up opened on 2026-09-17 has been "filled" 14 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 14 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -6.67% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 25.8 percentage points (the stock lost 24.7% while the market gained 1.0%) | -25.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 37.8 percentage points (the stock lost 34.0% while the market gained 3.8%) | -37.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 63.6 percentage points (the stock lost 46.2% while the market gained 17.5%) | -63.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 19.7 percentage points (the stock lost 4.8% while the market gained 15.0%) | -19.7% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 27% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.6% of the share price. | -27.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 33% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.10 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -33.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 23% below the average price paid since it last reported on 2026-08-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $1.81 — a volume-weighted average of daily closes over 41 sessions, not a true tick-by-tick VWAP. | -22.7% |
Price levels it has turned at before
ALLO last closed at $1.40 on 2026-10-08. Since 2024-10-08 it has turned at 0 prices below its last close and 12 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.52 | Resistance | 8.6% above the last close | turned there twice · 2025-06-10 to 2025-10-09 |
| $1.56 | Resistance | 11.8% above the last close | turned there three times · 2025-04-08 to 2026-02-12 |
| $1.69 | Resistance | 20.7% above the last close | turned there twice · 2025-03-04 to 2025-07-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $2.23.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 34 trading days, since 2026-08-21.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$9.00 range $4.00 – $14.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ALLO
- Consensus EPS estimate-$0.1407 next reporting period, as of 2026-10-09
- Estimate change, 30 days$0.00 from -$0.1407, on 2026-09-07, 32-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of net losses and the need for significant additional capital to fund operations and clinical development.","High dependence on the success of lead product candidates; failure to demonstrate safety and efficacy in clinical trials would significantly harm the business.","Clinical development risks associated with novel technologies, including the potential for unforeseen serious adverse events."]
What changed in the latest 10-Q
AI-assisted comparison of ALLO's 10-Q filed 2026-08-12 against the prior one filed 2026-05-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing states ALPHA3 is currently enrolling at over 80 sites across the United States, Canada, South Korea and Australia (older filing stated more than 60 sites in North America with global expansion underway in South Korea and Australia).
- Newer filing adds that the company is continuing activities to support the potential expansion of ALPHA3 into the European Union, subject to applicable regulatory approvals and operational requirements.
- Newer filing states international expansion of ALPHA3 is expected to bring the trial to approximately 100 sites worldwide (older filing stated global expansion was expected to bring the trial to more than 80 sites worldwide).
- Newer filing adds that the company recently amended the protocol to add a non-randomized observational cohort of approximately 140 MRD-negative patients to be followed to further characterize MRD test performance, and states this cohort is not expected to impact the enrollment timeline for the existing randomized MRD-positive portion of the trial.
- Newer filing adds that the protocol amendment expanded the disease subtypes that may qualify patients for enrollment to include transformed follicular lymphoma, transformed marginal zone lymphoma and follicular lymphoma grade 3B.
- Newer filing specifies the amended ALPHA3 trial is expected to enroll approximately 220 MRD-positive randomized patients (older filing stated approximately 220 patients without specifying MRD-positive randomized).
- Removed:
- Older filing states ALPHA3 is enrolling across more than 60 sites in North America with site activation and patient screening underway in South Korea and Australia, which was replaced by the newer filing's site description.
- Older filing includes interim futility analysis details: MRD negativity observed in 58.3% (7/12) of patients in the cema-cel arm compared with 16.7% (2/12) in the observation arm; ctDNA levels decreased from baseline by a median of 97.7% in the cema-cel arm compared with a median increase of 26.6% in the observation arm; primary and secondary endpoints remain blinded; no treatment-related serious adverse events, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, graft-versus-host disease or treatment-related hospitalizations were reported in the cema-cel arm.
- Older filing states 'Statistical design of the trial and the prespecified study conduct remain the same,' which was replaced in the newer filing by wording about the statistical design and prespecified conduct of the randomized MRD-positive portion remaining unchanged.
- Reworded:
- Newer filing changes the interim futility analysis cutoff description from 'which was triggered when the 24th patient completed Day 45 MRD assessment' (older) to 'which was triggered when the 24th patie' (truncated in the newer text).
- Newer filing changes the sentence about the statistical design from 'Statistical design of the trial and the prespecified study conduct remain the same' (older) to 'The statistical design and prespecified conduct of the randomized MRD-positive portion of the trial remain unchanged' (newer).
- Notes:
- The newer filing text is truncated mid-sentence after 'the 24th patie,' so changes after that point cannot be fully assessed.
- Page number differs between filings: newer text marked page 22, older text page 19; this is formatting/metadata, not a substantive MD&A content change.
Risk Factors
- Reworded:
- [object Object]
- Notes:
- The newer filing text is truncated at the start of 'Risks Related to Our Fina', and the older filing text is also truncated at the same point, so changes after that point in the full Risk Factors section cannot be assessed.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 1 sell ($62958) — 1 selling insider
- Last 180 days · read to 2026-10-040 buys · 2 sells ($85101) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-21. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ALLO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ALLO as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 85,462,884
- Reported value $177,762,797
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ALLO's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ALLO had 59,600,117 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ALLO had 17.3% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.26 days to cover at the same settlement.
- Reported short interest (shares) 59,600,117
- Short interest (% of shares outstanding) 17.3%
- Prior settlement (shares) 59,114,784
- Reported change 0.82%
- Days to cover (reported) 11.26
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Gilead Sciences (Kite) (GILD)
- Novartis (NVS)
- Bristol Myers Squibb (BMY)
- Johnson & Johnson (JNJ)
- Cellectis (CLLS)
- CRISPR Therapeutics (CRSP)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ALLO vs…
ALLOGENE THERAPEUTICS INC is found in…
Frequently asked questions
What does ALLOGENE THERAPEUTICS INC (ALLO) do?
Allogene Therapeutics is a clinical-stage immuno-oncology company developing off-the-shelf, allogeneic T-cell therapies derived from healthy donors. Its pipeline focuses on treating cancer and autoimmune diseases, including large B-cell lymphoma (LBCL), renal cell carcinoma (RCC), and various autoimmune conditions like systemic lupus erythematosus.
What sector is ALLOGENE THERAPEUTICS INC (ALLO) in?
ALLOGENE THERAPEUTICS INC (ALLO) is classified in the Health Care sector. Its industry is biotechnology / immunotherapy. It trades on NASDAQ.
Who are ALLOGENE THERAPEUTICS INC's (ALLO) competitors?
Notable peers of ALLOGENE THERAPEUTICS INC (ALLO) include Gilead Sciences (Kite), Novartis, Bristol Myers Squibb, Johnson & Johnson and Cellectis. This peer set is informational only — not financial advice.
Is ALLOGENE THERAPEUTICS INC (ALLO) overbought or oversold right now?
ALLOGENE THERAPEUTICS INC (ALLO) is currently in oversold territory (its 14-day RSI is 20, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ALLO come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.